Story
Insulet Stock Tumbles After Company Cuts Full-Year Revenue Guidance

Shares of Insulet Corporation (NASDAQ: PODD) plunged to a new 52-week low after the company significantly reduced its full-year revenue growth forecast, citing challenges with patient adoption and retention for its Omnipod insulin pump system. The updated outlook overshadowed a quarterly earnings beat and prompted a wave of downgrades from Wall Street analysts.
Guidance Cut Sparks Sell-Off
In its Q2 2026 earnings release, Insulet management lowered its full-year U.S. Omnipod growth forecast to a range of 17% to 19%, down from a prior estimate of 20% to 22%. The company also trimmed its guidance for total constant-currency revenue growth to 20% to 22%, from a previous range of 21% to 23%, while its Q3 revenue guidance also came in below analyst expectations.
According to CEO Ashley McEvoy, the revision was driven by lower-than-anticipated retention and utilization rates among new type 2 diabetes patients during their first 90 days. The company's updated guidance prudently assumes these trends will not improve during the second half of 2026.
Wall Street Downgrades
The revised forecast led to swift action from several investment banks, which added to the selling pressure on the stock. A number of analysts downgraded their ratings and slashed their price targets for Insulet.
Ad- JPMorgan: Downgraded the stock to Neutral from Overweight and cut its price target to $152 from $275, citing expectations of decelerating sales growth through the rest of 2026 and into 2027.
- Wells Fargo: Lowered its rating to Equal Weight from Overweight, slashing its price target to $144 from $255. Analysts noted that management now anticipates U.S. new patient starts will be flat to slightly down in 2027.
- Oppenheimer: Downgraded PODD to Perform from Outperform, arguing the challenges in the type 2 diabetes market appear to be "structural rather than merely execution-related."
Market and Sector Impact
The combination of the guidance cut and analyst downgrades sent Insulet shares to a new 52-week low of $126.40. The negative sentiment also affected competitors in the diabetes device sector, with shares of Tandem Diabetes and DexCom also falling in sympathy.
The sell-off suggests investors are reassessing the growth trajectory and pace of market penetration for insulin pump technology in the broader type 2 diabetes population. An ongoing securities-fraud class-action lawsuit related to prior manufacturing issues was also cited as an overhang on investor sentiment.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.